Search hospitals > Wisconsin > Milwaukee
Medical College of Wisconsin
Claim this profileMilwaukee, Wisconsin 53226
Global Leader in Parotid Gland Cancer
Global Leader in Cancer
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Lymphoma
Conducts research for Breast Cancer
1364 reported clinical trials
135 medical researchers
Summary
Medical College of Wisconsin is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Parotid Gland Cancer, Cancer, Adult T-Cell Leukemia/Lymphoma, Lymphoma, Breast Cancer and other specialties. Medical College of Wisconsin is involved with conducting 1,364 clinical trials across 1,356 conditions. There are 135 research doctors associated with this hospital, such as Nirav Shah, MD, Meghen B. Browning, William Bradley, MD, and Binod Dhakal, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Cancer
Global LeaderStage IV
Stage III
Stage I
Top PIs
Nirav Shah, MDMedical College of Wisconsin2 years of reported clinical research
Studies Lymphoma
Studies Coronavirus
18 reported clinical trials
24 drugs studied
Meghen B. BrowningChildren's Hospital of Wisconsin19 years of reported clinical research
Studies Cancer
Studies Neuroblastoma
16 reported clinical trials
40 drugs studied
William Bradley, MDMedical College of Wisconsin2 years of reported clinical research
Studies Parotid Gland Cancer
Studies Ovarian Cancer
17 reported clinical trials
41 drugs studied
Binod Dhakal, MDMedical College of Wisconsin4 years of reported clinical research
Expert in Multiple Myeloma
Expert in Plasma Cell Neoplasm
17 reported clinical trials
27 drugs studied
Clinical Trials running at Medical College of Wisconsin
Lung Cancer
Breast Cancer
Non-Small Cell Lung Cancer
Parotid Gland Cancer
Breast cancer
Ovarian Cancer
Cancer
Prostate Cancer
Skin Cancer
Chronic Lymphocytic Leukemia
Ifinatamab Deruxtecan
for Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Recruiting2 awards Phase 36 criteria
Dato-DXd + Pembrolizumab
for Advanced Lung Cancer
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.
Recruiting2 awards Phase 313 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Medical College of Wisconsin?
Where is Medical College of Wisconsin located?
Who should I call to ask about financial aid or insurance network?
What insurance does Medical College of Wisconsin accept?
What awards or recognition has Medical College of Wisconsin received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.